Richard L. Schilsky will be leaving his role as inaugural principal investigator of the American Society of Clinical Oncology-led Targeted Agent and Profiling Utilization Registry study after a decade of leadership.
Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.
